Pharma companies reduce price of Remdesivir Injection even as black market prices jump 10x

Acute shortage had led to a huge spike in the price of Remdesivir injection use in Covid-19 treatment, as per govt instructions pharma companies have slashes the rates while raising production of the anti-viral drug.

Here are some of the the revised prices

• Cadila: Rs 899 (vs Rs 2,800)
• DRL: Rs 2,700 (Vs Rs 5,400)
• Cipla: Rs 3,000 (vs Rs 4,000)
• Mylan: Rs 3,400 (vs rs 4,800)

Remdesivir is considered a key anti-viral drug in the fight against COVID-19, especially in adult patients with severe complications.

Seven Indian companies are producing Injection Remdesivir under voluntary licensing agreement with Gilead Sciences, USA. They have an installed capacity of about 38.80 lakh units per month. At least six manufacturers have received approval for setting up additional sites that could scale up the production capacity of Remdesivir by 1 million vials per month.